NCT02062632 · OUTCOME

Patient Preference for Continued Therapy at Initial Dose and Crossover

Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy · Source last updated 2019-10-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: At initial Day 1 dose and Day 3 crossover dose.

Analysis population: Only patients who submitted data on patient preference are evaluable for this outcome measure. Since none of the patients crossed over to the optional phase of the study, this secondary outcome could not be analyzed.

Groups in this outcome

Placebo

Patients receive placebo oral solution (swish, gargle for 30 seconds, and slowly swallow) on day 1.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Placebo	0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

counts
group Id
OG000
value
0
units
Participants

groups

description
Patients receive placebo oral solution (swish, gargle for 30 seconds, and slowly swallow) on day 1.
id
OG000
title
Placebo

population Description

Only patients who submitted data on patient preference are evaluable for this outcome measure. Since none of the patients crossed over to the optional phase of the study, this secondary outcome could not be analyzed.

reporting Status

POSTED

time Frame

At initial Day 1 dose and Day 3 crossover dose.

title

Patient Preference for Continued Therapy at Initial Dose and Crossover

type

SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice